RUNX1 and acute myeloid leukemia: al reported a prevalence of 0.1% using RUNX1 FISH to ascertain 21q22 amplification in their AML cohort and using the same approach, we found a frequency of 0.2% in our AML cohort, while Weber et al. described a higher prevalence of 0.7% using ERG FISH [13, 14].